A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
A study to evaluate the safety and tolerability of subcutaneous (SC) AMG 701 in participants with relapsed or refractory multiple myeloma (RRMM) to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D)
Relapsed/Refractory Multiple Myeloma
DRUG: AMG 701|DRUG: AMG 701
Number of participants who experience dose-limiting toxicities (DLTs), 28 days|Number of participants who experience one or more treatment-emergent adverse events (TEAEs), up to approximately 9 months|Number of participants who experience one or more treatment-related TEAEs, up to approximately 9 months|Number of participants with abnormal changes in vital signs, up to approximately 9 months|Number of participants with abnormal changes in electrocardiograms (ECGs) findings, up to approximately 9 months|Number of participants with abnormal changes in clinical laboratory tests, up to approximately 9 months
Maximum serum concentration (Cmax) of AMG 701, up to approximately 8 months|Time to maximum concentration (Tmax) of AMG 701, up to approximately 8 months|Area under the concentration-time curve (AUC) of AMG 701, up to approximately 8 months|Minimum concentration over the dosing interval (Ctrough) of AMG 701, up to approximately 8 months|Incidence of anti-AMG 701 antibody formation, up to approximately 9 months|Overall response (OR), up to approximately 8 months|Best overall response (BOR), up to approximately 8 months|Time to response, up to approximately 8 months|Duration of response (DOR), up to approximately 8 months|Progression-free survival (PFS), up to approximately 3 years|Overall survival (OS), up to approximately 3 years
A study to evaluate the safety and tolerability of subcutaneous (SC) AMG 701 in participants with relapsed or refractory multiple myeloma (RRMM) to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D)